Phase (Ph) 1 study of oral seviteronel (VT-464), a dual CYP17-Lyase (L) inhibitor and androgen receptor (AR) antagonist, in patients (pts) with advanced AR+ triple negative (TNBC) or estrogen receptor (ER)+ breast cancer (BC).
暂无分享,去创建一个
A. Bardia | T. Traina | M. Danso | H. Ali | N. Gabrail | R. Fleming | S. Lemon | W. Moore | J. Eisner | A. Gucalp | M. Kurman | N. Dacosta